Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors

NCT01184807 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumour

Interventions

DRUG: OPB-51602

Sponsor

Otsuka Beijing Research Institute